Endovascular Access, Wires, Sheaths, Closure, and Complication Rescue

15.1Principles of endovascular access

Endovascular procedures rely on the Seldinger technique, in which a controlled puncture is followed by passage of a flexible guidewire and coaxial sheath advancement to avoid an unprotected arteriotomy Seldinger 1953. Transluminal access treats the access site as a gateway to cross and dilate obstructive disease without open surgical exposure, requiring the access route to accommodate the target lesion, device profile, and bailout pathway Dotter and Judkins 1964.

Wire choice follows a wire-first discipline. Guidewires group by diameter into three platforms: 0.035 inch for aortoiliac and large-bore work, 0.018 inch for intermediate targets, and 0.014 inch for tibial and chronic-total-occlusion crossing. Negotiate the vessel first with a soft atraumatic or steerable-tip wire (Bentson, angled hydrophilic Glidewire), then exchange to a stiff or extra-stiff body wire (Amplatz Super Stiff, Lunderquist Extra Stiff) to track large-bore sheaths and devices Large-bore Access Review 2024. Hydrophilic wires cross tight or tortuous segments but are exchanged out before device delivery, since their low friction and non-radiopaque tip raise the risk of dissection, perforation, and loss of position.

15.2Access route selection

Transfemoral common-femoral access is the default for most peripheral and large-bore interventions. For elective bifurcated endovascular aneurysm repair (EVAR), totally percutaneous access and surgical cut-down demonstrate comparable short-term mortality, aneurysm exclusion, hematoma, and wound infection rates, while the percutaneous approach reduces operative time by approximately 21 minutes Cochrane EVAR Access 2023. A dedicated EVAR closure substudy reported a 6% major complication rate for percutaneous closure versus 10% for surgical exposure, with shorter overall procedure times (107 versus 141 minutes) PEVAR Substudy 2013. Large-bore transfemoral access requires preprocedural computed tomography angiography (CTA) to assess vessel diameter, calcification, and tortuosity, alongside an established bailout pathway Large-bore Access Review 2024. Size the access quantitatively by the sheath-to-femoral-artery ratio (SFAR), the sheath outer diameter divided by the minimal common-femoral luminal diameter. An SFAR above 1.05 predicts a higher rate of VARC major vascular complications (30.9% versus 6.9%) and higher 30-day mortality (18.2% versus 4.2%), so keep the ratio at or below 1.0, most achievable when the common femoral is non-calcified Hayashida 2011. A device's stated French size denotes its inner lumen; the outer diameter runs roughly 1.5 to 2 French larger and is what must fit the artery. Heavy anterior-wall or circumferential calcification is a relative contraindication to percutaneous large-bore access regardless of diameter.

Radial access evidence must be separated by procedure. Coronary consensus recommendations are not proof that radial access is preferred for every peripheral, trauma or large-bore intervention Transradial Consensus 2018. In a retrospective 65-patient trauma series, radial access succeeded in 63 patients; one radial thrombosis was reported. This supports feasibility for selected trauma embolization within endovascular trauma management (EVTM), not superiority to femoral access Safety efficacy 2019. A separate 2024 review summarizes peripheral radial interventions rather than reporting this trauma cohort Radial Artery 2024. Access planning still requires compatible vessel size, catheter length/device profile and a conversion route. Peripheral radial consensus addresses ultrasound-guided entry and patent hemostasis, but its advice should not be extrapolated to devices the radial artery cannot accommodate Chinese Transradial Consensus 2023.

Brachial access is a discrete upper-extremity option for antegrade lower-limb or visceral work, kept to smaller sheaths to limit brachial-sheath bleeding and nerve injury; in fenestrated or branched EVAR, upper-extremity access carries higher stroke, myocardial infarction, and mortality than total transfemoral routes VQI Upper Extremity Access 2023. When antegrade crossing of an infrainguinal chronic total occlusion fails, ultrasound-guided retrograde puncture of a distal target (distal superficial femoral or popliteal, or a tibial or pedal vessel: anterior tibial or dorsalis pedis, posterior tibial, or peroneal) with a low-profile 0.014 or 0.018 inch system enables retrograde or bidirectional crossing. A meta-analysis of 1,910 limbs reported 96% technical success with infrequent access-site perforation (2.1%) and flow-limiting dissection (0.6%) Giannopoulos 2021.

When transfemoral access is unavailable (affecting 5% to 12% of transcatheter structural candidates), extrathoracic routes (transaxillary, transcarotid, transcaval) are prioritized over intrathoracic routes (transaortic, transapical) because intrathoracic approaches carry up to a two-fold higher early mortality risk Alternative TAVR Access 2024. Transcaval access demands CT identification of a calcium-free aortocaval target and nitinol occluder closure Transcaval Access 2022. For complex fenestrated or branched EVAR, total transfemoral access using steerable sheaths is preferred over upper-extremity adjuncts, as upper-extremity access is associated with higher stroke, myocardial infarction, and mortality rates VQI Upper Extremity Access 2023.

15.3Entry and closure technique

Ultrasound-guided common-femoral access improves first-pass success (odds ratio 3.35), reduces time to successful access by approximately 17 seconds, and decreases unintentional vein puncture (odds ratio 0.26) compared with anatomic landmark guidance Cochrane Ultrasound Access 2025. In the prespecified UNIVERSAL subgroup analysis of coronary procedures with fluoroscopic landmarking, ultrasound guidance reduced the 30-day composite of BARC 2, 3 or 5 bleeding or major vascular complications among patients receiving vascular closure devices (11.8% versus 23.4%; OR 0.44, 95% CI 0.23–0.82), but bleeding alone was not significantly reduced; no significant composite benefit was demonstrated without a closure device UNIVERSAL Trial Substudy 2023. An individual participant-level meta-analysis of four coronary trials, including UNIVERSAL (2,441 participants), found fewer major vascular complications or BARC 3 bleeding with ultrasound guidance overall (2.8% versus 4.5%; OR 0.61, 95% CI 0.39–0.94) and fewer major vascular complications, without a significant reduction in bleeding alone. Its closure-device subgroup also suggested greater composite benefit, but actual device use was a post-randomisation variable and subgroup findings remain hypothesis-generating. These findings establish neither a closure-device-mediated mechanism nor absence of benefit without a device. These predominantly small-bore coronary data do not establish the same effect size in large-bore or peripheral interventions Ultrasound guidance 2024.

Collagen-plug closure devices reduce groin hematoma and pseudoaneurysm rates compared with manual compression, whereas metal-clip and suture-based devices show no significant difference from compression for these outcomes Cochrane VCD 2016. Antegrade closure carries similar overall and bleeding complication rates to common-femoral retrograde closure, provided there is adequate working length and imaging-confirmed entry Antegrade Closure Meta-analysis 2021.

Large-bore closure results depend on the device, deployment strategy, anatomy and study population. Nonsignificant differences in a pilot study do not establish equivalent safety. The larger CHOICE-CLOSURE trial found more index-hospital access-site/related vascular complications with a pure MANTA strategy than with primary ProGlide, despite faster hemostasis. These TAVR results should not be generalized to every plug/suture product or to EVAR MASH Trial 2021 · CHOICE-CLOSURE 2021.

This is a representative comparison of verified labels, not a market inventory or declaration of availability in every jurisdiction. Use the exact supplied device's instructions for use (IFU), not a class-wide French-size assumption.

Hybrid suture/plug approaches and venous electrophysiology closure studies require their own population and device-label assessment; venous closure is not interchangeable evidence for femoral arterial hemostasis.

15.4Access complication rescue

Access-site complications occur in approximately 3.5% of peripheral vascular interventions. Among recorded access complications, 74.4% were minor; 9.7% required transfusion and 5.4% thrombin injection, both classified as moderate, while 10.5% required surgery and were classified as severe. Severe complications were associated with 6.1% versus 1.4% 30-day mortality; the study did not establish that every moderate complication carried that mortality rate VQI 2014. Expanding hematoma, loss of distal perfusion, new bruit, disproportionate groin pain, hypotension, or closure-device failure dictate immediate rescue intervention.

Large-bore access complication management

1. Recognize and temporize: Identify closure failure or bleeding instability promptly. Apply manual compression and initiate volume resuscitation while assessing the mechanism of failure.
2. Endovascular or hybrid bailout: When feasible, preserve wire access and use balloon control while identifying the injury. Covered-stent exclusion can treat selected perforations or pseudoaneurysms when landing zones preserve essential branches and distal flow. Additional closure devices are an option only for a suitable residual puncture; they do not correct every arterial injury. Common-femoral covered-stent use may be outside device labeling Mid- Long-Term 2025.
3. Open repair: Proceed to prompt operative control when bleeding cannot be controlled, distal ischemia persists, anatomy prevents safe exclusion, or infected/damaged tissue requires repair or debridement. Hemodynamic instability determines urgency, not an automatic prohibition of a rapidly effective endovascular bridge. Compare the fastest feasible open, endovascular and hybrid routes rather than allowing repeated unsuccessful percutaneous attempts to delay control Mid- Long-Term 2025.
4. Conduit construction: Construct open iliac conduits for hostile iliofemoral anatomy when percutaneous limits are exceeded or unrecoverable failure is predicted preoperatively Open Iliac Conduits 2025.

Radial artery occlusion occurs in 5.3% of transradial procedures, rising to 7.1% in patients older than 60 years compared with 3.8% in younger cohorts Radial Artery Occlusion 2024. Distal radial access complications are more frequent in women (7.5%) than men (4.1%), though major bleeding is absent Distal Radial Access Registry 2025. Radial rescue relies on preprocedural sizing, protocol-driven anticoagulation, and patent hemostasis. Distal axillary access with a femoral safety wire provides an alternative percutaneous rescue route in highly selected cohorts Percutaneous Trans-axilla 2022.

15.5Postoperative care and follow-up

Access-site surveillance targets the early identification of hematoma, ischemia, femoral stenosis, pseudoaneurysm, and infection. Clinical examination dictates post-procedure care; imaging is reserved for specific symptoms, abnormal physical findings, or observed closure failure. Comparable femoral measurements between closure groups do not establish that ultrasound can safely be omitted. Document hemostasis and distal perfusion, and obtain targeted vascular imaging for a new mass, bruit, persistent pain, ischemia or suspected closure failure; the imaging plan also depends on the original procedure and device. Evidence boundaries dictate follow-up intensity; complication profiles derived from coronary or structural heart populations are not uniformly translatable to complex endovascular aneurysm repair or extracorporeal membrane oxygenation access.

15.6Areas of controversy

The superiority of specific large-bore closure devices remains unsettled. Pilot studies with nonsignificant comparisons do not establish equivalence. CHOICE-CLOSURE demonstrated a difference between specified MANTA and ProGlide strategies in transfemoral TAVR; applicability to other devices, EVAR and hostile access anatomy remains a separate question CHOICE-CLOSURE 2021. A reduction in a composite of bleeding and vascular complications should not be described as a proven reduction in major bleeding alone. In the UNIVERSAL closure-device subgroup and the individual-participant-data meta-analysis that includes UNIVERSAL, actual closure-device use was a post-randomisation variable. These subgroup findings are hypothesis-generating and do not establish closure-device performance as the mechanism of benefit from ultrasound guidance UNIVERSAL Trial Substudy 2023 · Ultrasound guidance 2024. Furthermore, the safety of total percutaneous access in hostile femoral arteries lacks robust randomized support, as foundational percutaneous EVAR evidence rests on low-certainty trials that routinely exclude adverse anatomies Cochrane EVAR Access 2023.

Further reading

• Plug- Versus Sutured-Based Vascular Closure Devices for Large Bore Arterial Access: A Systematic Review and Meta-Analysis. (2025). Large-bore access closure devices; procedure mix limits generalization. Plug vs Suture Meta-analysis 2025
• Technical Success and Complication Rates of Retrograde Arterial Access for Endovascular Therapy for Critical Limb Ischaemia: A Systematic Review and Meta-Analysis. (2021). Retrograde arterial access in limb-threatening ischemia. Giannopoulos 2021